High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients

Circulation. 2004 Jul 20;110(3):285-91. doi: 10.1161/01.CIR.0000135587.92455.0D. Epub 2004 Jul 12.

Abstract

Background: LDL modification by endogenous advanced glycation end products (AGEs) is thought to contribute to cardiovascular disease of diabetes. It remains unclear, however, whether exogenous (diet-derived) AGEs influence glycoxidation and endothelial cell toxicity of diabetic LDL.

Methods and results: Twenty-four diabetic subjects were randomized to either a standard diet (here called high-AGE, HAGE) or a diet 5-fold lower in AGE (LAGE diet) for 6 weeks. LDL pooled from patients on HAGE diet (Db-HAGE-LDL) was more glycated than LDL from the LAGE diet group (Db-LAGE-LDL) (192 versus 92 AGE U/mg apolipoprotein B) and more oxidized (5.7 versus 1.5 nmol malondialdehyde/mg lipoprotein). When added to human endothelial cells (ECV 304 or human umbilical vein endothelial cells), Db-HAGE-LDL promoted marked ERK1/2 phosphorylation (pERK1/2) (5.5- to 10-fold of control) in a time- and dose-dependent manner compared with Db-LAGE-LDL or native LDL. In addition, Db-HAGE-LDL stimulated NF-kappaB activity significantly in ECV 304 and human umbilical vein endothelial cells (2.3-fold above baseline) in a manner inhibitable by a MEK inhibitor PD98059 (10 micromol/L), the antioxidant N-acetyl-l-cysteine, NAC (30 mmol/L), and the NADPH oxidase inhibitor DPI (20 micromol/L). In contrast to Db-LAGE-LD and native LDL, Db-HAGE-LDL induced significant soluble vascular cell adhesion molecule-1 production (2.3-fold), which was blocked by PD98059, NAC, and DPI.

Conclusions: Exposure to daily dietary glycoxidants enhances LDL-induced vascular toxicity via redox-sensitive mitogen-activated protein kinase activation. This can be prevented by dietary AGE restriction.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetylcysteine / pharmacology
  • Administration, Oral
  • Antioxidants / pharmacology
  • Cardiovascular Diseases / prevention & control
  • Diabetes Complications / prevention & control
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / diet therapy
  • Diabetes Mellitus / enzymology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / enzymology
  • Endothelium, Vascular / metabolism
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Female
  • Glycation End Products, Advanced / administration & dosage
  • Glycation End Products, Advanced / pharmacology*
  • Humans
  • Lipoproteins, LDL / blood
  • Lipoproteins, LDL / chemistry
  • Lipoproteins, LDL / toxicity*
  • Male
  • Middle Aged
  • NADPH Oxidases / antagonists & inhibitors
  • NF-kappa B / metabolism
  • Oxidation-Reduction
  • Transcriptional Activation
  • Vascular Cell Adhesion Molecule-1 / biosynthesis

Substances

  • Antioxidants
  • Glycation End Products, Advanced
  • Lipoproteins, LDL
  • NF-kappa B
  • Vascular Cell Adhesion Molecule-1
  • NADPH Oxidases
  • Extracellular Signal-Regulated MAP Kinases
  • Acetylcysteine